Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "hypomethylating" Condition: Myelodysplastic Syndromes Clear all
Recruiting Early Phase 1 Interventional

Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

NCT07071155
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Overlap Neoplasms, Chronic Neutrophilic Leukemia
Interventions
Momelotinib, Azacitidine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 1, 2026, 10:00 AM EDT
Not listed Phase 1 Interventional

Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)

NCT03258359
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
PACTN
Biological
Lead sponsor
PersImmune, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 1, 2026, 10:00 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents

NCT01246076
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Lenalidomide
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Scottsdale, Arizona • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Sep 1, 2026, 10:00 AM EDT
Completed Phase 2 Interventional Results available

Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

NCT02159872
View directory record Official record
Conditions
Leukemia
Interventions
Omacetaxine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 1, 2026, 10:00 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

NCT02281084
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Oral Azacitidine, Durvalumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 1, 2026, 10:00 AM EDT
Completed Phase 1 Interventional Results available

Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents

NCT02936752
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Entinostat, Pembrolizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
19
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 1, 2026, 10:00 AM EDT
Completed Phase 1 Interventional

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

NCT02117219
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
MEDI4736 Evaluate MEDI4736 in MDS, VIDAZA, tremelimumab
Biological · Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Sep 1, 2026, 10:00 AM EDT
Completed Phase 1 Interventional

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS

NCT02732184
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Co-ArgI-PEG modified human arginase I
Drug
Lead sponsor
Immedica Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 1, 2026, 10:00 AM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

NCT02530463
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome
Interventions
Azacitidine, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 1, 2026, 10:00 AM EDT
Not listed Phase 1Phase 2 Interventional

Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS

NCT02576301
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Interventions
Phase 1 - OXi4503, Phase 1 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 1, 2026, 10:00 AM EDT
Withdrawn Phase 1Phase 2 Interventional

CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome

NCT03929211
View directory record Official record
Conditions
Myelodysplastic Syndromes, Progressive Disease
Interventions
CPI-613, Hydroxychloroquine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Buffalo, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 1, 2026, 10:00 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

NCT03151304
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Pracinostat, Azacitidine
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Duarte, California • San Diego, California • Augusta, Georgia + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 1, 2026, 10:00 AM EDT
Recruiting Phase 1 Interventional

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

NCT03896269
View directory record Official record
Conditions
Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, High Risk Chronic Myelomonocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory High Risk Myelodysplastic Syndrome
Interventions
Liposome-encapsulated Daunorubicin-Cytarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 1, 2026, 10:00 AM EDT
Recruiting Phase 1 Interventional

Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome

NCT06502145
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Azacitidine Level 1, Azacitidine Level 0, Iadademstat Level 1, Iadademstat Level 0
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 1, 2026, 10:00 AM EDT
Completed Phase 1 Interventional

Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia

NCT00671697
View directory record Official record
Conditions
Myelodysplastic Syndromes and Leukemia, Myeloid, Acute
Interventions
Arsenic Trioxide, Decitabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Sep 1, 2026, 10:00 AM EDT
Completed Phase 2 Interventional

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

NCT03672539
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine, Quality-of-Life Assessment
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 1, 2026, 10:00 AM EDT
Active, not recruiting Phase 2 Interventional

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

NCT05201066
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Interventions
decitabine, spartalizumab, sabatolimab, azacitidine, venetoclax, INQOVI (oral decitabine)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Portland, Oregon • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 1, 2026, 10:00 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

NCT02929498
View directory record Official record
Conditions
Myelodysplastic Syndrome, Myelodysplastic Syndromes
Interventions
GSK2879552, Azacitidine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Augusta, Georgia • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Sep 1, 2026, 10:00 AM EDT
Withdrawn Phase 2 Interventional

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

NCT05766514
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Cladribine, Cytarabine, Decitabine, azacitidine or decitabine, Venetoclax
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Sep 1, 2026, 10:00 AM EDT
Active, not recruiting Phase 2 Interventional

CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS

NCT04668885
View directory record Official record
Conditions
Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia, Myelodysplastic Syndromes
Interventions
CPX-351
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 1, 2026, 10:00 AM EDT
Terminated Phase 2 Interventional Results available

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

NCT03146871
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia
Interventions
Azacitidine, Decitabine, Laboratory Biomarker Analysis, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein
Drug · Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 1, 2026, 10:00 AM EDT
Withdrawn Phase 2 Interventional

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

NCT01520805
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
CPI-613
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cranbury, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 1, 2026, 10:00 AM EDT
Recruiting Phase 1 Interventional

Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

NCT07270978
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
Interventions
CD33 FPBMC
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 1, 2026, 10:00 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant

NCT01812252
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome
Interventions
Azacitidine (AZC), Decitabine, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
4
States / cities
Scottsdale, Arizona • Cleveland, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 1, 2026, 10:00 AM EDT